Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation

Elisabeth Mémin, Mainul Hoque, Mohit R. Jain, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-0474

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/11/12/0008-5472.CAN-13-0474.DC1.html

Cited Articles
This article cites by 51 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/2/552.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation

Elisabeth Mémin1, Mainul Hoque1, Mohit R. Jain1, Debra S. Heller2, Hong Li1, Bernadette Cracchiolo3, Hartmut M. Hanauske-Abel1,3, Tsafi Pe’ery1,4, and Michael B. Mathews1

Abstract

Cancer etiology is influenced by alterations in protein synthesis that are not fully understood. In this study, we took a novel approach to investigate the role of the eukaryotic translation initiation factor eIF5A in human cervical cancers, where it is widely overexpressed. eIF5A contains the distinctive amino acid hypusine, which is formed by a posttranslational modification event requiring deoxyhypusine hydroxylase (DOHH), an enzyme that can be inhibited by the drugs ciclopirox and deferiprone. We found that proliferation of cervical cancer cells can be blocked by DOHH inhibition with either of these pharmacologic agents, as well as by RNA interference–mediated silencing of eIF5A, DOHH, or another enzyme in the hypusine pathway. Proteomic and RNA analyses in HeLa cervical cancer cells identified two groups of proteins in addition to eIF5A that were coordinately affected by ciclopirox and deferiprone. Group 1 proteins (Hsp27, NM23, and DJ-1) were downregulated at the translational level, whereas group 2 proteins (TrpRS and PRDX2) were upregulated at the mRNA level. Further investigations confirmed that eIF5A and DOHH are required for Hsp27 expression in cervical cancer cells and for regulation of its key target 1kB and hence NF-kB. Our results argue that mature eIF5A controls a translational network of cancer-driving genes, termed the eIF5A regulon, at the levels of mRNA abundance and translation. In coordinating cell proliferation, the eIF5A regulon can be modulated by drugs such as ciclopirox or deferiprone, which might be repositioned to control cancer cell growth. Cancer Res; 74(2); 552–62. ©2013 AACR.
Cell proliferation was inhibited, and morphologic changes occurred, after treatment with the drugs or eIF5A silencing. We devised a proteomic approach (Fig. 1B) to identify proteins that are regulated by both CPX and DEF using HeLa cells as a model. Five proteins, in addition to mature eIF5A itself, were identified whose synthesis and accumulation were coordinate-ly affected by these drugs. The proteins play key roles in cancer cell proliferation, survival, and metastasis and fall into 2 groups. Group 1 proteins were downregulated by the drugs at the translational level, whereas group 2 proteins were upregulated at the mRNA level. The group 1 protein Hsp27, a molecular chaperone, is a cancer biomarker and potential target for cancer therapy (18). RNA interference experiments showed that hypusyl-eIF5A is required for Hsp27 synthesis and modulates transcription via NF-κB. Our data suggest that mature eIF5A1 regulates the expression of a set of genes, designated the eIF5A regulon, that are required for cell proliferation. Taken together, these findings prompt the design of clinical trials to examine the use of the drugs CPX and DEF and related agents, in anti-cancer therapy.

Materials and Methods

Immunohistochemistry

Cervical cancers were diagnosed by an experienced pathologist as squamous cell carcinoma (12 samples) or adenocarcinoma (9 samples). Tissue sections were stained for eIF5A using NIH-353 antibody (kindly provided by Dr. M.H. Park) and with Ki-67 antibody (Dako) as described previously, in compliance with an Institutional Review Board-approved protocol allowing anonymous use of archival, formalin-fixed, paraffin-embedded biopsy material (5).

Cell culture

Cells from the American Type Culture Collection were maintained as recommended and seeded 1 day before treatment. CPX (Sigma-Aldrich) and DEF (Calbiochem) were freshly dissolved in PBS and added to the medium for 24 to 72 hours.

Immunoblotting

Cells were lysed as described previously (19). Proteins were assayed (DC Protein Assay, BioRad) and 1 to 20 μg samples were resolved by SDS-PAGE. After transfer to polyvinylidene difluoride (PVDF) membranes, blots were probed with primary antibody followed by horseradish peroxidase–conjugated secondary antibody (Jackson Immunoresearch). Rabbit anti-peroxiredoxin 2 antibody was from Upstate Cell Signaling, mouse anti-eIF5A and anti-NM23 from Becton Dickinson (BD; Transduction Laboratories), mouse anti-TrpRS and anti-Hsp27 from Novus Biologicals, rabbit anti-DJ-1 from Cell Signaling Technology, and mouse anti-β-actin and anti-α-tubulin from Sigma. Rabbit anti-DOHH antibody was kindly provided by Dr. Myung Hee Park (NIH/NIDCR, Bethesda, MD). Signal was detected using enhanced chemiluminescence.

RNA interference

For cell growth assays, HeLa cells were transfected with 20 nmol/L siRNA and U2OS cells with 50 nmol/L siRNA using Hiperfect (Qiagen). Cells were harvested at 72 hours.
posttransfection unless otherwise stated. siRNA sequences (sense/antisense) were as follows: eIF5A1 (Ambion), 5'-GGUCCACUGCUGGUUGAUUUTT/5'-AAUACCACAGAUG-GACCTT; luciferase (Ambion) for negative control for HeLa cell proliferation assays, 5'-CGUACGGGAAUCCUGGATT/5'-UCGAAAGUACCGGUACGTG. DHS and DOHH “ON-TARGET plus SMART pool” and nontargeting control siRNAs were from Dharmacon. For luciferase assays, HeLa cells were transfected with 50 nmol/L siRNA using Hiperfect (Qiagen). Cells were re-seeded at 48 hours and co-transfected at 72 hours with the HIV-1 molecular clone pHIV-3 lucE– and pCMV-Renilla plasmid using Jet-PEI (polyplus transfections). Cells were harvested 24 hours later and expression of reporter genes analyzed (19).

**Metabolic labeling**

HeLa cells were incubated for 21 hours with 30 μmol/L CPX or 200 μmol/L DEF, washed twice with PBS and once with Dulbecco’s Modified Eagle Medium (DMEM) lacking methionine and cysteine, then incubated for 3 hours in the same medium containing 50 μCi/mL of Trans[35S]-label (MP Biomed) with drug as appropriate. Cells were washed with ice-cold PBS before scraping. For measurement of hypusine and deoxypusine synthesis, cells were labeled with [3H]-spermidine for 24 hours and analyzed as described previously (20).

**Two-dimensional gel electrophoresis and protein identification**

HeLa cell extracts were prepared by incubation for 30 minutes at 4°C in lysis buffer (50 mmol/L Tris-Cl, pH 7.5, 150 mmol/L NaCl, 0.5% Nonidet P-40, 1 mmol/L dithiothreitol, 0.1% SDS, 50 mmol/L NaF, 1 mmol/L Na orthovanadate, and protease inhibitor cocktail from Sigma-Aldrich), and analyzed in 2-dimensional (2D) gels (21). Nonradioactive gels were fixed (40% ethanol, 10% acetic acid), stained with SYPRO Ruby (BioRad), and scanned on a Typhoon scanner (GE Healthcare). Radioactive gels were dried under vacuum and exposed to autoradiography film. Spot intensities were compared visually in 3 replicate experiments for each of the analysis using spots with unchanged densities as landmarks. Spots from stained gels were processed for MALDI-TOF-TOF mass spectrometry analysis (Supplementary Table S1; ref. 21).

**RNA extraction and real-time PCR**

Total RNA was isolated using TRizol (Invitrogen Life Technologies). cDNA was generated using 2 μg total RNA, random hexamers, and MultiScribe reverse transcriptase (Applied Bio- systems). PCR was carried out in an Applied Biosystems 7500 apparatus, using SYBR Green mix (Roche Applied Biosystems) and AmpErase (Applied Biosystems). Primers were: Hsp27, 5'-CAGCATCG/5'-CTCCTTCAAGCAGACGAGCTC; and β-actin, 5'-AAA-TCGTGCGTGACATTAAGG/5'-AGCACTGTGTTGGCGTGACAG.

**Results**

**elf5A expression in human cervical carcinoma**

elf5A is overexpressed in a number of malignant tissues including vulvar high-grade intraepithelial neoplasia (VIN), the precursor to vulvar cancer (5). To evaluate expression in cervical cancer, we conducted immunohistochemical studies with NIH-353 antibody, which recognizes mature hypusyl-elf5A1 (5), and with Ki-67 antibody to identify proliferating cells. NIH-353 immunoreactivity located strictly to Ki-67–positive areas in both major types of cervical cancer, that is, invasive solid tumor cords and nests in squamous cell carcinoma and invasive vacuole-containing glandular sheets of columnar cells in adenocarcinoma (Fig. 2A). These observations indicate that hypusyl-elf5A1 is highly expressed in the vast majority of cervical tumors. Correspondingly, hypusyl-elf5A is abundant in HeLa cells, derived from cervical adenocarcinoma. Immunoblotting with NIH-353 antibody revealed varying levels of expression among cancer cell type groups (Fig. 2B). Comparison with U2OS cells (derived from osteosarcoma) indicates a range of at least 5-fold in proliferating cell lines (Fig. 2C). The high level of mature elf5A1 observed in HeLa cells corroborates previous observations (20), matching its high expression in cervical cancer biopsies (Fig. 2A).

**Mature elf5A is required for cell growth**

RNA silencing was deployed to determine whether elf5A1 overexpression is directly involved in cell proliferation. Reduction in HeLa cell number became evident 4 days after transfection with siRNA directed against elf5A1 (si5A) compared with control siRNA (siC; Fig. 3A, top). Inhibition of cell proliferation correlated with the reduction in the elf5A1 protein level (Fig. 3A, bottom). Notably, both declined more rapidly in U2OS cells that contain less elf5A (Fig. 3B). Furthermore, depletion of the elf5A modifying enzyme DOHH (Fig. 1A) also reduced proliferation of HeLa and U2OS cells (Fig. 3A and B). These data indicate that hypusyl-elf5A is critical for cell proliferation in both of these cancer cell lines.

**CPX and DEF inhibit elf5A maturation and cell proliferation**

We used HeLa cells to study the effects of 2 drugs, CPX and DEF, which inhibit the hydroxylation of deoxypusyl-elf5A by DOHH (Fig. 1A). To monitor the drugs’ action in HeLa cells, we measured hypusine formation by labeling elf5A with [3H]-spermidine. Inhibitor constants, K_I, were 6.25 μmol/L for CPX and 152 μmol/L for DEF (Supplementary Fig. S1). Pharmacologic concentrations of CPX (30 μmol/L) or DEF (200 μmol/L; refs. 10, 19) suppressed hypusine labeling by >90% with concomitant appearance of deoxypusine (Fig. 3C). Immature forms of elf5A1 accumulated in the presence of the drugs as revealed by 2D gel electrophoresis (Fig. 3D). Without drug treatment, elf5A1 was represented by a single predominant spot with a pl of about 5.3, corresponding to hypusyl-elf5A (22). Treatment with CPX or DEF led to the appearance of 2
spots with more acidic pIs (~5.2 and ~5.1) associated with acetylated forms of deoxyhypusyl-eIF5A (23). Thus, the drugs prevented the maturation of eIF5A and led to the accumulation of its immediate precursor, deoxyhypusyl-eIF5A.

Consistent with their inhibitory action on DOHH, both drugs rapidly inhibited HeLa cell proliferation (Fig. 3E), similar to the effects of eIF5A or DOHH knockdown (Fig. 3A). Drug-treated cells retained >93% of control viability at 24 hours, exhibited minimal apoptosis, and were arrested in the G1 to S-phase of the cell cycle (Supplementary Fig. S2), as reported previously (6, 7, 15, 24). They exhibited morphologic changes and an increase in size (Supplementary Fig. S3), reminiscent of the phenotype of eIF5A-deficient yeast (25, 26).

**Modulation of protein expression by CPX and DEF**

eIF5A is believed to be the target of a specific class of proteins (24, 25). As CPX and DEF inhibit eIF5A maturation and HeLa cell proliferation, we sought to identify cellular proteins that are downstream targets of the drugs. Our strategy combined the analysis of protein levels and translation in drug-treated and untreated cells using 2D gels (Fig. 1B). Representative gel images are presented (Supplementary Fig. S4), together with sections of stained gels (Fig. 4A) and [35S]-labeled gels (Fig. 4B) containing spots whose intensities changed with drug treatment. Several spots decreased in intensity as expected (e.g., spot 10) but others were observed to increase (e.g., spot 6).

We enumerated the spots in both the staining and labeling analyses that increased, decreased, or were unaltered in intensity after drug treatment (Fig. 4C). The overwhelming preponderance of spots did not change in intensity with CPX or DEF. Among those that did change, attention was focused on proteins whose labeling and accumulation varied in parallel (criterion 1, Fig. 1B). With CPX, 5 spots decreased and 3 spots increased in both types of analysis; with DEF, 8 spots decreased and 5 increased in both types of analysis (highlighted in Fig. 4C).

As the drugs might impinge on cellular pathways in addition to that involving eIF5A, we further limited consideration to spots that were affected in the same way by CPX and DEF (criterion 2). Seven spots varied coordinately with the 2 drugs: 3 increased and 4 decreased. It is notable that all 3 proteins upregulated by CPX and nearly all (4 of 5) of the downregulated proteins were shared with DEF and that most (3 of 5) of the proteins upregulated by DEF and half (4 of 8) of the downregulated proteins were in common. This high degree of concordance lends confidence that the changes reflect a common pharmacologic target and biochemical pathway.

**Identification of DOHH-dependent proteins**

Proteins whose synthesis was affected by both drugs were eluted from unlabelled gels, analyzed by mass spectrometry, and identified through database searches (Fig. 5A;
Supplementary Table S1). Identifications were checked by immunoblotting with specific antibodies (criterion 3, Fig. 1B). All were confirmed except for one upregulated protein identified as 4-hydroxyphenylpyruvate dioxygenase (4-HPD), which could not be detected by immunoblotting (data not shown). Accordingly, 4-HPD is not included in the list of identified proteins and was not pursued further.

In addition to eIF5A1, the downregulated proteins are heat shock protein 27 (Hsp27), DJ-1 (PARK7), and non-metastatic protein 23 (NM23), designated group 1.
upregulated proteins, designated group 2, are peroxiredoxin 2 (PRDX2) and tryptophanyl-tRNA synthetase (TrpRS).

Differential regulation of gene expression by the drugs

Immunoblotting and real-time (RT)-PCR were carried out to examine the effect of CPX and DEF on the identified proteins and their cognate mRNAs (Fig. 5B–G).

Consistent with the action of the drugs on its posttranslational modification (Fig. 3C and D), eIF5A1 expression was not significantly affected at the total protein level (Fig. 5B, filled bars) or at the RNA level (Fig. 5B, gray bars).

On the other hand, CPX and DEF reduced the expression of Hsp27, NM23, and DJ-1 proteins (Fig. 5C–E, filled bars), in agreement with the 2D gel data. The degree of inhibition was about 50% with CPX and about 30% with DEF. Exceptionally, the DEF-induced reduction in the level of DJ-1 was less, possibly because the drug affects the oxidation status of this protein, resulting in a change that is registered primarily in 2D gels (27). As with eIF5A1, RT-PCR revealed no significant changes in transcript levels (Fig. 5C–E, gray bars), indicating that the downregulation of Group 1 proteins by the drugs is due to translational control.

The drug-induced upregulation of PRDX2 and TrpRS was confirmed by immunoblotting (Fig. 5F and G, filled bars). Increased expression of these proteins was accompanied by increased levels of their transcripts (Fig. 5F and G, gray bars), indicating that CPX and DEF upregulate group 2 proteins at the level of mRNA transcription or stability. Interestingly, the increase in TrpRS RNA markedly exceeded that of the protein, possibly reflecting its secretion as an angiostatic factor (discussed below).

Mature eIF5A modulates Hsp27 levels and NF-κB activity

To document the connection between a drug target and eIF5A modification, we selected Hsp27 for further study. Hsp27 expression is increased in high-grade intraepithelial neoplasia and squamous cell carcinoma of the cervix (28) and several other cancers. It has been directly implicated in tumor progression (29) and radio- and chemoresistance (18). Furthermore, Hsp27 activates signaling via the transcription factor NF-κB by facilitating the turnover of its inhibitor IκB (30).

Our findings with CPX and DEF (Fig. 5C) suggested that hypusyl-eIF5A is required for elevated Hsp27 synthesis and, by extension, for NF-κB–dependent transcription. To examine these inferences, we depleted HeLa cells for eIF5A1 or its modifying enzymes. Immunoblotting showed that siRNA directed against eIF5A1, DHS, or DOHH reduced the level of Hsp27 (Fig. 6A), as with drug treatment (Fig. 5C) and led to concomitant elevation of IκB as predicted (Fig. 6A).

NF-κB is essential for HIV-1 transcription (31), and CPX and DEF have been shown to inhibit expression from the HIV-1 promoter (19). We therefore depleted HeLa cells for eIF5A1, DHS, or DOHH and then transfected with an HIV-1 molecular clone expressing firefly luciferase. Reporter gene expression was inhibited by 50% to 60% in all cases (Fig. 6B). As IκB is barely detectable in control cells (Fig. 6A), these results indicate that hypusyl-eIF5A plays an important role in regulating Hsp27 levels and NF-κB activity in HeLa cells.

Discussion

The identification of 2 groups of target proteins sensitive to CPX and DEF has implications for the regulation of gene expression by eIF5A and for the exploration of the drugs’ therapeutic potential in cancer.

Robustness of target identification

The cornerstone of our strategy for identifying drug targets was multiplexed 2D gel analysis, and its reliability follows from
<table>
<thead>
<tr>
<th>Group</th>
<th>Protein</th>
<th>NCBI protein accession no. (gi)</th>
<th>pI</th>
<th>MW (Da)</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>eIF5A: Eukaryotic initiation factor 5A</td>
<td>4503545</td>
<td>5.07</td>
<td>16,832</td>
<td>Protein synthesis</td>
</tr>
<tr>
<td>1</td>
<td>Hsp27: Heat shock protein 27</td>
<td>4504517</td>
<td>5.98</td>
<td>22,783</td>
<td>Chaperone</td>
</tr>
<tr>
<td>1</td>
<td>NM23: nonmetastatic protein 23</td>
<td>17512044</td>
<td>5.81</td>
<td>17,149</td>
<td>Nucleoside diphosphate kinase</td>
</tr>
<tr>
<td>1</td>
<td>DJ-1: Parkinson disease 7</td>
<td>50513593</td>
<td>6.33</td>
<td>19,891</td>
<td>Sensor of oxidative stress. Transcriptional activator.</td>
</tr>
<tr>
<td>2</td>
<td>PRDX2: Peroxiredoxin-2 isoform a</td>
<td>32189392</td>
<td>5.66</td>
<td>21,892</td>
<td>Redox regulation. Antioxidant.</td>
</tr>
<tr>
<td>2</td>
<td>TrpRS: Tryptophanyl-tRNA synthetase</td>
<td>340368</td>
<td>5.8</td>
<td>53,165</td>
<td>Protein synthesis. Angiogenesis inhibitor.</td>
</tr>
</tbody>
</table>

Figure 5. Identification and expression of drug-regulated proteins. A, identity and properties of proteins affected by both CPX and DEF and identified by mass spectrometry. Molecular weights (MW) and isoelectric points (pI) were calculated from protein sequences (www.phosphositeplus.org and www.expasy.org). B–G, gene expression analysis of drug effects in HeLa cells. Top, immunoblot analysis of the downregulated (B–E) and upregulated (F and G) proteins with actin as a control. Bar graphs, protein levels relative to actin were evaluated by immunoblotting (filled bars) and corresponding RNA levels were assayed using RT-PCR (gray bars). Data are means of 3 independent experiments with SD.
Although both drugs chelate iron (8, 9), the lowering of intracellular iron is insufficient for this activity (19, 32). Rather, they appear to fit into the enzyme’s active site and abstract its iron, causing structural collapse (19). While contributions of other pathways cannot be ruled out, the evidence points to eIF5A maturation as the primary target with far-reaching consequences including inhibition of cell proliferation resulting from the depletion of hypusyl-eIF5A and/or the accumulation of deoxyhypusyl-eIF5A (Fig. 3).

The 5 newly identified drug-sensitive proteins (Fig. 5A) are not documented cellular binding partners of eIF5A or its modifying enzymes (33), nor do they uniformly harbor proline-rich translational signals characterized for the bacterial eIF5A homolog EF-P (Supplementary Fig. S5). Rather, they appear to be secondary drug targets regulated by hypusyl-eIF5A, as shown for Hsp27 (Fig. 6), and they fall into 2 groups distinguished by both the direction of the drug response and the level at which it is exerted.

Group 1 targets are downregulated by CPX and DEF apparently at the level of translation, consistent with the function of eIF5A in protein synthesis (34). Depletion of eIF5A in yeast decreases protein synthesis only partially (25, 35), however, implying that it functions as a selective translational enhancer for group 1 mRNAs.

Group 2 targets are upregulated at the RNA level by CPX and DEF, indicating that their transcription or mRNA stability is increased. eIF5A has been implicated in mRNA turnover in yeast (35) and human cells (Hoque and colleagues, unpublished results), suggesting that eIF5A-dependent selective turnover could be responsible for group 2 mRNA regulation.

Coordinate regulation of these proteins has also been observed in proteomic studies of cells treated with other agents. For example, the expression of eIF5A and NM23 is induced and that of PRDX2 and TrpRS is repressed, after p53 activation by mitomycin C (36). We therefore advance a model (Fig. 7) in which hypusyl-eIF5A1 modulates a regulon, or RNA operon (37), that controls cell proliferation and possibly other processes such as the response to oxidative stress. Mechanistically, we envision that eIF5A (or possibly one or more of its target proteins) preferentially binds a subset of cellular mRNAs (38) and recruits additional proteins that favorably influence its activity with SD.

Putative eIF5A regulon

Results presented here (Fig. 3C and D) establish that CPX and DEF inhibit DOHH in HeLa cells, leading to a deficit in hypusine and accumulation of deoxyhypusine in eIF5A. Although both drugs chelate iron (8, 9), the lowering of...
mRNA-binding proteins that impinge differentially on the 2 groups of gene products, thereby facilitating the translation of group 1 mRNAs and accelerating the turnover of group 2 mRNAs.

Oncological implications

Like eIF5A, group 1 proteins are associated with cell proliferation and cancer (39–41). The best characterized is the chaperonin Hsp27, a marker for unfavorable prognosis in many human cancers and a potential therapeutic target (18, 29, 42, 43). Similarly, DJ-1 is highly expressed in a number of human cancers (41). DJ-1 enhances cell survival via activation of NF-kB and its silencing inhibits cell proliferation (41, 44). NM23 catalyzes the phosphorylation of nucleoside diphosphates and its expression is related to cell proliferative activity (45). Although initially considered an inhibitor of metastasis, accumulating data reveal differential expression of NM23 isoforms and indicate a more complex relationship with cancer. Recent work identified NM23 as a predictor of poor survival in pancreatic cancer (46). Furthermore, all three group 1 proteins associate with factors that control cell shape, providing a plausible explanation for the morphologic changes brought about by CPX and DEF, which are possibly related to cell motility changes and metastasis (Supplementary Fig. S4; ref. 41). Thus, the downregulation of Hsp27, DJ-1, and NM23 by CPX and DEF suggests that these drugs could have a therapeutic effect in malignancies characterized by overexpression of group 1 proteins.

Conversely, group 2 proteins can exert negative effects on cell proliferation. High TrpRS expression correlates with lower risk of recurrence and increased survival in patients with colorectal cancer (47). In addition to its canonical intracellular role in tRNA aminoacylation, N-terminally truncated forms of TrpRS are secreted and have anti-angiogenic activity, blocking VEGF-induced cell proliferation and migration (48, 49). Thus, like IFN-γ administration, drug-induced increase of TrpRS is consistent with anti-angiogenic and antiproliferative activity that could discourage tumor growth. PRDX2 is a member of a family of cellular peroxidases that have a complex relationship with tumor formation (50). The growth of breast cancer cells that metastasize to lung was inhibited by PRDX2 knockdown, whereas overexpression in bone metastatic breast cancer cells reduced the skeletal tumor burden and bone destruction (51). This suggests that the enzyme prevents tumor growth in hypoxic conditions, possibly signaled by deoxyhypusyl-eIF5A, although it protects against oxidative stress in oxygen-rich environments. Therefore, upregulation of group 2 proteins by CPX and DEF may restrain the growth of certain tumors.

In summary, we propose that eIF5A coordinates a set of genes at the level of translation (increased) and of mRNA abundance (decreased, possibly by facilitating mRNA decay). These genes define an eIF5A regulon that activates cell proliferation, and loss of eIF5A function has anti-cancer effects. The widely used drugs CPX and DEF interfere with eIF5A posttranslational modification and function, therefore qualify as candidates for exploratory oncologic trials and further drug development. Consistent with this conclusion, oral CPX has shown promise in treating patients with acute myelogenous leukemia in a recent proof-of-concept trial (A.D. Schimmer, personal communication).

Disclosure of Potential Conflicts of Interest

D.S. Heller has ownership interest (including patents) with Hanauske-Abel HM, Park MH, Wolf EC, Clement PMJ, Cracchiolo BM, Heller D (2002) Method of detecting proliferating cells by antibodies and their derivatives directed at the hypusine region of eIF-5A. United States Patent pending (NMS-02-71). H.M. Hanauske-Abel has ownership interest (including patents) from Cornell University owned US patent #6,046,219 in deferiprone. B. Cracchiolo and H.M. Hanauske-Abel have ownership interest (including patents) from Rutgers University and NIH co-owned US patent #7,141,589 in ciclopirox, Rutgers University and NIH co-owned US patent #7,141,589 in ciclopirox (for Dr. Cracchiolo, spouse). No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: E. Memin, M. Hogue, H.M. Hanauske-Abel, T. Pe'ery, M.B. Mathews

Development of methodology: E. Memin, M. Hogue, T. Pe'ery, M.B. Mathews

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Memin, M. Hogue, M.R. Jain, D.S. Heller

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Memin, M. Hogue, M.R. Jain, D.S. Heller, H. Li, B. Cracchiolo, H.M. Hanauske-Abel, T. Pe'ery, M.B. Mathews

Writing, review, and/or revision of the manuscript: E. Memin, M. Hogue, M.R. Jain, D.S. Heller, H. Li, B. Cracchiolo, H.M. Hanauske-Abel, T. Pe'ery, M.B. Mathews

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Hogue

Study supervision: M. Hogue, H. Li, T. Pe'ery, M.B. Mathews

Acknowledgments

The authors thank Anita Antes for invaluable assistance, Dr Jyoti Mundra for contributions to RNA interference experiments, and the Foundation of UMDNJ for support. Apologies for limited literature citation.

Received February 13, 2013; revised September 18, 2013; accepted October 4, 2013; published OnlineFirst November 12, 2013.
References


Drug Targets and eIF5A Hydroxylation in Cervical Cancer Cells

Published OnlineFirst November 12, 2013; DOI: 10.1158/0008-5472.CAN-13-0474

www.aacrjournals.org

Cancer Res; 74(2) January 15, 2014

561

Downloaded from cancerres.aacrjournals.org on May 11, 2014. © 2014 American Association for Cancer Research.


